FMP

FMP

Enter

PTCT - PTC Therapeutics, In...

photo-url-https://images.financialmodelingprep.com/symbol/PTCT.png

PTC Therapeutics, Inc.

PTCT

NASDAQ

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

54.5 USD

1.74 (3.19%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

159.74M

305.44M

437.86M

582.02M

714.73M

1.05B

1.56B

2.3B

3.39B

5B

Revenue %

-

91.21

43.35

32.93

22.8

47.57

47.57

47.57

47.57

Ebitda

1.51M

106.37M

143.57M

221.51M

233.41M

293.81M

433.57M

639.83M

944.22M

1.39B

Ebitda %

0.95

34.82

32.79

38.06

32.66

27.86

27.86

27.86

27.86

Ebit

-8.72M

87.53M

120.19M

197.15M

209.3M

240.06M

354.27M

522.8M

771.5M

1.14B

Ebit %

-5.46

28.66

27.45

33.87

29.28

22.76

22.76

22.76

22.76

Depreciation

10.24M

18.84M

23.39M

24.36M

24.11M

53.74M

79.31M

117.04M

172.71M

254.88M

Depreciation %

6.41

6.17

5.34

4.19

3.37

5.1

5.1

5.1

5.1

EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep